Follow-up Order for Women in the Process of Proceeding with Antiretroviral Treatment at the CHU de Brazzaville: Prevalence and Associated Factors

Ossibi Ibara BR^{1, 2,} , Bintsene Mpika Gickelle^{1, 3}, Adoua Doukaga T^{1, 2}, Bouambo G^{1, 3}, Potokoué Mpia NSB^{1, 3}, Balekouzou A², Ekat M², Angonga Pabota E², Bendet P², Itoua C^{1, 3} and Iloki H^{1, 3}

¹Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Congo

²Infectious Diseases Service, CHU de Brazzaville, Congo

³Obstetrics and Gynecology Service, CHU de Brazzaville, Congo

Cite this paper:
Ossibi Ibara BR, Bintsene Mpika Gickelle, Adoua Doukaga T, Bouambo G, Potokoué Mpia NSB, Balekouzou A, Ekat M, Angonga Pabota E, Bendet P, Itoua C and Iloki H. Follow-up Order for Women in the Process of Proceeding with Antiretroviral Treatment at the CHU de Brazzaville: Prevalence and Associated Factors. American Journal of Infectious Diseases and Microbiology. 2022; 10(2):83-87. doi: 10.12691/ajidm-10-2-4

Abstract

Objective. Determine the prevalence of follow-up stops at women in order to stay at the CHU of Brazzaville and identify the associated factors. Patients and method. Transversal study, with a descriptive and analytical view of spatients immunodepressed by the VIH, having stopped the follow-up for at least one month in the Brazzaville CHU Infectious Diseases Service during the January 2019 period in June 2021. Results: A total of 110 patients were admitted (25.9%) with an average age of 33.2 ± 9.1 years, single women (51.8%), students (n = 29; 26.4%), Nullipares (n = 82; 29.1%), having a maternity leave ((n = 41; 37.8%). They had several sexual partners (n = 43; 39.1%) and were infected by VIH1 (98, 2%). The prolonged fever (n = 42; 38.2%) and chronic diarrhea (n = 22; 20%) were the main reasons for consultation. They were classified OMS 3 (n = 54; 49.1 %) and had as opportunistic infections tuberculosis (n = 41; 37.3%) and toxoplasmosis (n = 25; 22.7%). The CD4 was <200 / mm3 (n = 52; 53.6%) and the VIH was discovery in hospitalization (n = 59; 53.6%). The TARV was made of TDF + FTC + EFV (n = 51; 46.4%) and DTG + 3TC + TDF (n = 7; 6.4%). Secondary effects were cauchemars (n = 66; 60%), diarrhea (55, 43,6) and factors associated with treatment arrest were distance dispensation ARV domicile> 5 km (p = 0.04), the stage of the OMS3 (p = 0.02), the troubles of sommeil (p = 0, 001). Conclusion: Prevalence of follow-up stops among women in the process of proceeding with antiretroviral treatment is relatively high and this, in line with several factors in particular, the toxicity of antiretroviral molecules, the elimination of the drug dispensing site and also the advanced immunosuppression with its correlation of opportunistic infections in particular tuberculosis.

Keywords:
follow-up arrest women in procrastination age prevalence associated factors Brazzaville

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	UNAIDS. Report on global AIDS Epidemic 2019. Geneva: UNAIDS; 2019.
[2]	Sondo Ouedraogo. Analyse des déterminants de survenue de grossesse chez les femmes infectées par le VIH, sous trithérapie antirétrovirale à Dakar. Mémoire CES de Maladies Infectieuses et Tropicales, Dakar 2007.
[3]	Soro BN, Koffi K, Brengues C, Coulibaly A, Houdier R, Kassi K, et al. L’infection par le VIH chez les femmes en âge de procréer à Sassandra (Côte-d’Ivoire). Cahiers santé 1993; 3: 31-6.
[4]	Sobesky M, Zoccarato AM, Magnien C, Rocca Serra P, Karaoui L, Carles G, Delattre P. L’infection par le VIH chez la femme enceinte en Guyane Française. Gynécologie Obstétrique et fertilité. 2003; 31(4): 343-349.
[5]	Dao S, Oumar AA, Coulibaly D, Sylla A, Coulibaly B, Diallo. Causes de décès des patients sous traitement antirétroviral dans le service des maladies infectieuses de l’hôpitla du point G à Bamako, Mali. Louvain Médical 2009; 128, 1: 25-29.
[6]	AKA dago-Akribi H, Cacou M-C. Désir d’enfant chez la mère séropositive ayant un enfant infecté par le VIH/Sida. African population study. 2004; 19(2): 103-114.
[7]	Aka Dago, Desgrés, Dossou R, Msellati P. Issues surrounding reproductive choice for women living with HIV in Abidjan, Côte d’Ivoire. Health Reproductive Matters, 1999, 7/ 20-29.
[8]	Ossibi Ibara BR, Antaon J., Kibimi C, Bitsené Mpika G, Adoua Doukaga, Angonga et al. Knowledge, attitudes and Practices of women of Childbearing Age with Regard to HIV in Brazzaville –Congo. Annal of Reviews and Research. 2019, 5(4): 42-48.
[9]	Manga NM, Diop SD, Ndour CT, Dia NM, Mendy A, Coudec M et al. Dépistage tardif de l’infection à VIH à la clinique des maladies infectieuses de Fann, Dakar : circonstances de diagnostic, itinéraire thérapeutique des patients et facteurs déterminants. Med Mal Infect. 2009; 39: 95-100.
[10]	Ossibi Ibara BR, Bemba ELP, Okemba Okombi FH, Mouloungui M, Adoua Doukaga T, Angonga Pabota et al. Opportunistic Infections in patients living with HIV at Brazzaville University Hospital: Prevalence and associated factors. American Journal of Infectious Diseases and Microbiology. 2020, 8 (1): 20-23.
[11]	Muller M, Wandel S, Colebunders R. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010: 10(4): 251-61.
[12]	PNLS. Lignes directrices nationales, Congo 2020; 23-27.
[13]	Katlama C., Tubiana R. Les traitements Antirétroviraux. Bilan des stratégies et indications thérapeutiques 2000; 23-37.
[14]	Sylla D. Le devenir des patients adultes VIH positifs à 6 mois après initiation au traitement antirétroviral à l’hôpital de Sikasso, [Thèse : Med], Bamako : FMOS, juillet 2017.
[15]	Molamba DA: Caractéristiques et devenir des patients perdus de vue sous traitement antirétroviral au sein des structures médicales appuyées par la coopération technique allemande dans la ville de Kinshasa, [Thèse : sante pub] Kinshasa : ISPED septembre 2009.
[16]	Mbou Essie DE, Ndziessi G, Ndinga H, Niama A, Mpandzou GA, Oyere G, Ibara JR. Preventing mother to child transmission of HIV: knowledges attitude and practices of antenatal care providers in Talangaï health district (Brazzaville). Health Sci. Dis 2020, vol.21, no.2, pp 118-122.
[17]	Djadou KE, Koffi KS, Saka B, Tépé EM, Vinyo DK, Tatagan-Agbi K. Connaissances, attitudes et pratiques des prestataires de soins en matière de prévention de la transmission du VIH de la mère à son enfant en 2010 au Togo. Med Trop 2011, vol.71, No.6, pp. 608-612.
[18]	Aubin PH, Cloutier K, Dubé F, Ferreira E, Bussières J-F, Lebel D, Bérard A. Observance du traitement antirétroviral chez les femmes enceintes atteintes du VIH avant et après un conseil pharmaceutique. http://www.pharmactuel.com/sommaires.
[19]	D’Arminio Monforte A, Cozzi-Lepri A, Phillips A. Interruption of highly active therapy in HIV clinical prectice: results from the Italian Cohort of antiretroviral –naive patients. J. Acquir Immune Defic Syndr.2005; 38: 407-416.